Q3 EPS Estimates for Belite Bio Lowered by Leerink Partnrs

Key Points

• Leerink Partners has reduced its Q3 2025 earnings estimates for Belite Bio to ($0.54) EPS, down from ($0.46), while also projecting continued losses through FY2026.
• Despite the earnings forecast, HC Wainwright maintains a "buy" rating for Belite Bio with a target price of $100.00, while the stock currently has a consensus rating of "Moderate Buy."
• Institutional investors have significantly increased their stakes in Belite Bio, with GAMMA Investing LLC raising its ownership by 9,391.6%, indicating growing confidence in the company despite the recent earnings adjustments.

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Free Report) - Research analysts at Leerink Partnrs lowered their Q3 2025 EPS estimates for Belite Bio in a report released on Monday, August 11th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of ($0.54) per share for the quarter, down from their previous estimate of ($0.46). The consensus estimate for Belite Bio's current full-year earnings is ($1.17) per share. Leerink Partnrs also issued estimates for Belite Bio's Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.05) EPS, FY2026 earnings at ($0.80) EPS, FY2027 earnings at $0.95 EPS and FY2028 earnings at $6.70 EPS.

Belite Bio (NASDAQ:BLTE - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.03). During the same quarter in the prior year, the firm earned ($0.31) EPS.

BLTE has been the subject of a number of other reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Belite Bio in a report on Thursday, May 15th. Wall Street Zen downgraded shares of Belite Bio from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Finally, HC Wainwright reissued a "buy" rating and set a $100.00 price objective on shares of Belite Bio in a research report on Thursday, July 3rd. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $96.67.

Belite Bio Stock Down 3.4%

Shares of Belite Bio stock traded down $2.35 during trading on Thursday, reaching $66.63. The company's stock had a trading volume of 44,722 shares, compared to its average volume of 49,584. Belite Bio has a 52-week low of $43.70 and a 52-week high of $86.53. The company has a market cap of $2.12 billion, a price-to-earnings ratio of -42.99 and a beta of -1.49. The firm's 50-day moving average is $62.77 and its two-hundred day moving average is $61.64.

Institutional Trading of Belite Bio

Hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its position in shares of Belite Bio by 43.3% during the first quarter. GAMMA Investing LLC now owns 1,849 shares of the company's stock valued at $122,000 after buying an additional 559 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Belite Bio in the 4th quarter worth approximately $155,000. EverSource Wealth Advisors LLC acquired a new position in Belite Bio in the 2nd quarter worth approximately $147,000. XTX Topco Ltd increased its holdings in Belite Bio by 30.9% in the 4th quarter. XTX Topco Ltd now owns 7,062 shares of the company's stock worth $446,000 after buying an additional 1,668 shares during the period. Finally, Marshall Wace LLP acquired a new stake in shares of Belite Bio during the 2nd quarter worth approximately $547,000. 0.53% of the stock is owned by hedge funds and other institutional investors.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.